Costco will not sell abortion pills after pressure from conservatives
For more than a year, Costco deliberated over whether to become certified to dispense mifepristone, the drug used first in the typical two-step regimen for a medication abortion. The procedure, often easier and cheaper than the surgical alternative, is the option women in America most frequently choose to end pregnancies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Edwards Lifesciences Stock: Analyst Estimates & Ratings
With a market cap of $45.2 billion, Edwards Lifesciences Corporation (EW) is a global leader in innovative products and technologies for treating advanced cardiovascular diseases. The company specializes in transcatheter and surgical heart valve solutions, as well as critical care monitoring systems, serving patients across the United States, Europe, Japan, and worldwide. Shares of the Irvine, California-based company have underperformed the broader market over the past 52 weeks. EW stock has increased 17.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 18.7%. Moreover, shares of the company have risen 4.9% on a YTD basis, compared to SPX's 9.7% return. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Looking closer, Edwards Lifesciences stock has outpaced the Health Care Select Sector SPDR Fund's (XLV) 12.1% decrease over the past 52 weeks. Shares of Edwards Lifesciences rose 5.5% following its Q2 2025 results on Jul. 24, with adjusted EPS of $0.67 and sales of $1.5 billion, both exceeding estimates and showing strong year-over-year growth. Segment strength was led by TAVR sales of $1.1 billion, TMTT sales of $134.5 million, and Surgical Structural Heart sales of $267 million. The company also raised its 2025 sales growth guidance to $5.90 billion - $6.10 billion and projected adjusted EPS at the high end of $2.40 - $2.50. For the fiscal year ending in December 2025, analysts expect EW's adjusted EPS to grow 2.9% year-over-year to $2.50. The company's earnings surprise history is promising. It topped or met the consensus estimates in the last four quarters. Among the 30 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on 15 'Strong Buy' ratings, one 'Moderate Buy,' 13 'Holds,' and one 'Strong Sell.' This configuration is more bullish than three months ago, with 12 'Strong Buy' ratings on the stock. On Jul. 25, RBC Capital raised its price target on Edwards Lifesciences to $89 with an 'Outperform' rating. As of writing, the stock is trading below the mean price target of $87.28. The Street-high price target of $101 implies a modest potential upside of 30% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
New York Times
an hour ago
- New York Times
The Best Medicine of All Was Each Other
Spoiler alert: They're fine. Kimberly Blair Hoffman likes to recall a lighter, sunnier side of the moment when Joshua Craig Woda reached out to her in October 2021, after seven and a half years. He messaged her on Facebook, despite already having her phone number. 'This is always a point she finds funny,' said Mr. Woda, 31, then on the verge of a bone-marrow transplant after a relapse of Hodgkin lymphoma, a type of cancer that affects the lymphatic system. He knew she would know exactly what he was going through. She already had two transplants herself. Each had first been diagnosed while they were students at Binghamton University. The two had met briefly, and awkwardly, in March 2014 when he was a sophomore and she a senior. His fraternity and her sorority had organized a dodgeball tournament, with them in mind — Dodgekins Lymphoma, a fund-raiser for the Leukemia and Lymphoma Society. They were both in remission at the time. Ms. Hoffman said that they 'exchanged stories, symptoms and diagnoses,' via email and text before the event. She had a stem cell transplant the previous January, and although she took the semester off, she felt well enough most weekends to drive from her parents' home in Brooklyn to visit her off-campus house. He had just finished eight rounds of chemotherapy while taking classes and living on campus. 'Aside from both being in other relationships,' she said, 'we were too young and too naïve going through this. How do you have a normal conversation?' Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Federal judge blocks Trump administration's broad birth control mandate exemptions
The Trump administration's religious and moral carve-outs to an ObamaCare requirement that all employer health plans cover contraception at no cost were blocked on Wednesday by a federal judge. District Judge Wendy Beetlestone in Philadelphia issued a summary judgment that the rules were arbitrary, capricious and an overreach of the authority of the agencies that wrote them in 2017. Under the rules, essentially any for-profit or nonprofit employer or insurer was allowed to exempt themselves from following the birth control mandate on moral and religious grounds. The rules also let publicly traded companies obtain a religious exemption, but not a moral one. The Affordable Care Act required employer health plans to cover at least one of 18 forms of birth control approved by the Food and Drug Administration. Religious groups and employers sued, and the Supreme Court in 2014 ruled 5-4 that the contraceptive mandate violated the Religious Freedom Restoration Act (RFRA) rights of closely held corporations whose owners had religious objections. Subsequent agency actions tried to find a balance, but the Trump administration in 2017 issued a blanket exemption. The rules didn't require employers to apply for an exemption because the administration said that would be a violation of their religious rights. Pennsylvania, New Jersey and dozens of other states sued to halt that broad expansion of exemptions and accommodations. That lawsuit reached the Supreme Court in 2020, where the justices upheld the Trump rules on technical grounds but did not address the underlying merits of the case. The case was sent back to the lower court, where a religious group, Little Sisters of the Poor, joined the lawsuit alongside the federal government in asking for summary judgment. Beetlestone, an appointee of former President Obama, wrote that the Trump administration's religious rule did not accomplish what the agencies purportedly wrote it to do, which was to resolve a conflict between the contraceptive mandate and RFRA. But the rule exemptions to organizations that are 'unlikely, if ever, to be capable of maintaining a religious objection, raising further doubts as to any 'rational connection' between the Rule and remedying potential conflicts with RFRA,' Beetlestone wrote. The Little Sisters of the Poor will appeal the ruling in the coming weeks, according to the Becket Fund for Religious Liberty, a nonprofit that represents the order. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
